Earnings call transcript Q4 2022

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon, ladies and gentlemen. Welcome to the Shattuck Labs Fourth Quarter and Full Year 2022 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. And I will now turn the call over to your host, Mr. Conor Richardson, Vice President of Investor Relations at Shattuck Labs. ahead. go please Conor,

Conor Richardson

press Good can call and and regarding results Relations close our updates. XXXX operator. was of financial Shattuck after section found issued full to on Labs financial market The business recent conference our afternoon and shattucklabs.com. reporting afternoon, you, our welcome results and everyone this the year release be Thank website fourth Investor quarter the

quarter business call, SL-XXXXXX, afternoon’s team Shattuck full overview including of XXXX, the fourth and our SL-XXXXXX. for a this During will clinical the leadership and program updates of year provide development lead

We and XXX refer throughout these call. will as to today’s XXX earnings

clinical upcoming be Officer, financial the update Co-Founder, on Schreiber, our on Dr. activities. review who closing who Chief Lini questions. quarter call will will Officer and our make open to by Executive review Pandite, an we fourth Dr. milestones, and Chief our remarks Officer, our key and Speaking Dr. for Neill Andrew will followed some Medical Taylor our and results Scientific will and provide will Financial today’s Mr. And will return progress then then ongoing full-year Chief call pipeline financial XXXX our Schreiber guidance.

Act remind XXXX. Before the risks and these from could within represent Reform statements webcast that those today the Private begin, Safe by the or management’s and you meaning Such uncertainties in statements. implied judgment certain as actual Harbor would we of involve like differ contains expressed results may cause I Litigation to materially of to Securities of today’s that forward-looking statements provisions of

the to XX, ended with website statements Report Form these or forward-looking February our XXXX our December on website XX-K today, which from risks for corporate on SEC’s filings refer our recent as most Annual of XXXX. year Any information on SEC, available other our more shattucklabs.com. XX, represent and are the views the and uncertainties, For please

over call Chief turn now Officer. will Taylor? I to the Executive our Dr. that, With Schreiber,

Taylor Schreiber

was Connor. XXX, focused did afternoon for you or and thank XXXX Agonist Shattuck our an operationally everyone advancing us today. job candidate. team clinical-stage products lead you, Thank Checkpoint year Redirected of clinical Good ARC and an excellent for joining our

XXX SIRPa-Fc-CDXXL the a checkpoint as protein, CDXX molecule as CDXX. which both As also important receptor a bi-functional to ligand is serves immune known fusion macrophage and reminder, activates an block stimulatory known

Linking therapeutic single these differentiates from within inhibitors two a other in clinical all XXX CDXX development. functions

CDXX clinical all course a pleased this that dose into the ovarian receptor. combination very human will the have dose we central and to to are a resistant trial Xa the in cohort, a which safely pharmacodynamic clinical of From believe Phase our dose-dependent of in cancer We validated and XXX a the Phase perspective, Phase of generated the doses escalation achieved saturated XXX platinum moment. activate of the Xa platform primary able of describe the study the to of that including the which I advance goals was XXX and monotherapy of patients trial hypotheses selection with ARC design shown our has including of CDXX in Xb manner, through in data completed first one

goals have to of XXX concentrations to be to of One observed serum was mg/kg effects have sharing to in the believed and completed at to very these forward into dose looking X this are important data also cytokines select the observed middle are cohorts. treated short, of medical immune study high IL-XX anti-tumor we variety A toward we other responses. pharmacodynamic and achieving meeting of we in-patients combination other findings a interleukin this of pharmacodynamic with support to number year. rapid primary trial the XX, move were widely the of this a in In the of pleased induction a

clinically a targeted immunogenic in with antibody another or combination rely with an or inhibitors cell that pro ADC CDXX agent regimens a to that agent signal upon see meaningful figures death. efficacy, order causes as to As such class, provides a

combination are the XXX For our where in syndrome. this cancer higher-risk combination agent to for several cohorts pegylated have In We patients our reason, as our with with moved combination trial acute leukemia short. is for with combined XXX and reasons. myeloid in PLD trial myelodysplastic PLD we ovarian pleased clinical expected Phase are cohort, ongoing known two being platinum-resistant are the There a in responses into trial for objective selected Xb in-patients liposomal first chemotherapy with cancer. both and studies, combination ovarian or doxorubicin clinical

PLD causes XXX ovarian combined preclinical shown antitumor of cells to when was cell cancer and activity in First, death enhance immunogenic studies. with

XX% standard-of-care known this platinum-resistant Thus, treated determining the strategy of Second, patients to due mechanistically multiple was of a clinical expect difficulty X we response combination to from do well-known rates contribution have response that as regimen with objective PLD PLD and is trials. is a of rate in the in low the the XX% where not setting Phase an the range and XXX driven monotherapy. PLD

antigen Shattuck soravtansine, and combination or The fully FR received known conjugate ovarian approval which alpha antibody-drug ImmunoGen result mirvetuximab targets for as ovarian cancer second alpha an receptor collaboration for cancer in called ImmunoGen. is cohort short. an of the accelerated between

alpha XXX FR that express a alpha, express just that be objective ovarian but of who is is XXX proportion FR of whose FR of low mirvetuximab. ovarian medium cancer high for potentiated patients, overall response The driven and initial improving also activity of of we If those express approval patients. across with of levels platinum-resistant rate not is benefit the the and preclinical of response levels of cancer mirvetuximab, FR tumor contribution more cells for cells that double patients biomarker and successful, tumors mirvetuximab terms expression. combination high this expected from Thus, subset both XX.X% In this alpha for response selected mechanistically alpha. could anti-tumor demonstrated the where in of than to combining observed for studies, duration is spectrum rates the levels a

we excited opportunity be XXX, and XXX the cancer underway our MDS. AML to well trial are for in-patients While in with ovarian are of high-risk in pleased also clinical about we

As were will overall soon be MDS may AML based many indications first the on where aware, first listeners and clinical antibodies high-risk and blocking approvals survival CDXX occur. are activity among demonstrated the

clinical year. Over and azacitidine half first milestones we of clinical both our our team monotherapy in the track dose-escalation on the and dose last data cohorts the combination for second initiated escalation half year, of this remain

comparison rates opens the first objective CDXX of response over of Although patient agents generation about published the tumor XXX, in population are contracted in component couple head-to-head important in inhibitors CDXX we has the we studies the in models which blockade for CDXX for and that like immunity blocking activation, to addition the antitumor antibodies. years, and acknowledge opportunity of which excited preclinical provides to this CDXX improved that past

to Let program, protein. SL-XXXXXX bi-functional us turn a fusion ligand PDX-Fc-OXXXL our now

the cohorts, greater, SL-XXXXXX further was and lymphoma. antitumor we of And to mg/kg XX% We the to program. XXX have which with justify target an our completed patients experienced the have decision response patients the XX and trial or development. tumors pharmacokinetics, to solid evaluating discontinue did thus, inhibitor in advanced XX overall multicenter the not made safety, clinical rate enrolling observe PDX After and we activity open-label of pharmacodynamics clinical tolerability,

patients inhibitor. The PDX clinical in-patients that for setting I already stimulation the a insufficient generated opportunity have and failed would the patients resistance OXXX with in-place our from to families suggest to this data participating treated in study. their who in like take the SL-XXXXXX thank overcome was to mechanisms

As forward remain to our medical high benefit will ongoing the which and trials SL-XXXXXX look the we experiencing focused therapeutics cancer coming combination novel data always, with need clinical with on delivering quarters. in unmet patients in

Dr. coming call Pandite, a that you will will CDXX these course now provide Officer, on Chief studies, is and data the more that, XXX XXXX. emerging our Lini? you who to the various illustrating are with inhibitor With will guidance provide the how turn of milestones over differentiated clinical Medical also I each of to with detail the over

Lini Pandite

and programs Taylor of operational execution made. pleased progress the have we Thanks, year afternoon. focus and good clinical continued high a was the of with XXXX and our am I

CDXX different clinical three Our clinical of our CDXX and XXX, inhibitor of data differentiated advancement clinical with coming each on agonist the focus studies. is on us see to

XXX Taylor As assess open-label, to now completed have with as our safety, the activity of dose-escalation and multi-center, mentioned, anti-tumor trial clinical of we in-patients platinum-resistant cancer. monotherapy administration Phase intravenous intended pharmacokinetics, pharmacodynamic effects tolerability, ovarian Xa

maximum As a trial, maximum kilogram a not this we dose we dose. tolerated XX administered in reached reach did per reminder a and mg of

to design the see not distress and the of of attribute the quarter, of gamma you As of portion to we did recall from deepening receptors. Fc last the absence will binding any XXX which evidence Fc we

expect the clinical full mid-XXXX. We report to trial portion from dose-escalation data this

pharmacodynamics the completion open-label to Phase trial Following XXX in doxorubicin is in in enrolling patients and in with dose with advanced Xb of patients of Xa our clinical antitumor combination with ovarian trial escalation to pharmacokinetics platinum-resistant and This selecting trial combination a evaluate doxorubicin. Phase liposomal activity dose, of tolerability, clinical XXX cancer. multi-center, liposomal we the intended safety,

from new We details I excited ImmunoGen. report collaboration very trial our data expect this with initial also mid-XXXX. about share to to combination am

patients to SL-XXXXXX and evaluate in with initiated enrollment efficacy Xb soravtansine have in cancer. We combination of with platinum-resistant ovarian Phase trial mirvetuximab in a the pharmacokinetic safety,

As as media expresses with than less may that defined of receptor or but beyond a equal XX% XXXXXX XX% alpha. receptor defined receptor receptor defined range folate than we than or Taylor and XX%, expression, XX%, high we broaden expression, patients greater to but high including folate the to receptor as alpha folate as just folate to those expression expression, across low of XX% and mirvetuximab receptor folate alpha less folate or than greater thus alpha equal expression greater alpha alpha of mentioned, enroll believe activity intend broader

the expect from half second to report XXXX. combination initial data this of in trial We

Now, this and attention monotherapy high-risk Phase safety, made pharmacodynamic tolerability, our the let the and with in us both our effects as clinical of XXX trial, with are In we and in have anti-tumor patients AML we progress evaluating trial to Xa/Xb azacitidine. activity pharmacokinetics in turn combination MDS.

and the is patient monotherapy and AML combination dose-escalation population. we to in Enrollment we and quarter planned in this intend As of data part cohort of azacitidine dose dosed and as this the TPXX staggered trial cohort patient of importantly dose to patient trial first monotherapy half of as the and combination in has parallel relapsed-refractory are in pretreated, trial azacitidine from we monotherapy we this high-risk of of which progressed the trial, reminder, heavily with a frontline in this enroll consistently the the a After XXXX. a fourth first clinical expect both combination population in a expected setting evaluate first frontline MDS. mutant in escalation the complete XXXX. Initial portion escalation portion XXX the

now to will Andrew? turn update. over discuss I to financial that, Neill Mr. our call With the

Andrew Neill

Thank everyone. you, Lini and good afternoon,

As of Conor XXXX would our like few full quarter are available to financial outset Report for and focus Annual I XX-K. mentioned in earnings full-year key the call, ended fourth December on and in a our Today, disclosures. XX, release points our at from the the press the results Form on

be continue We positioned to financially. well

of of As cash equivalents investments had XXXX, approximately XX, cash, $XXX.X December million. we and

million development our million, quarter to expenses $XX.X the fourth the In fourth of XXXX. quarter of were compared and research XXXX, $XX.X for

year to quarter December the development $XX.X and million For expenses compared our quarter fourth research general XXXX, December the XX, million XX, compared ended expenses XXXX, for year XXXX. the In of fourth as to our XXXX. administrative $X.X of and $X.X the $XX.X were were million for ended million

million general year $XX.X For to were the and XX, year administrative XX, XXXX, $XX.X December for ended as XXXX. million December expenses the compared ended

to the for diluted fourth of or XXXX for $X.XX and the loss $X.X fourth net per $X.XX loss XXXX diluted million per share. of $XX.X compared income per was of or $X.XX of a net Our basic a share quarter basic million quarter share, and

million $XX basic for was ended $XXX.X the basic year the December XXXX. $X.XX $X.XX year Our ended and XXXX or share per XX, as diluted compared net and or million for to per share diluted December XX, loss

Based we reiterate on operating development guidance our for our financial XXXX current and and plans, beyond.

equivalents cash planned and sufficient We to of We healthy in fund remain and position given and strong to half we into XXXX. committed in data clinical sheet our rate relates second our projected expected to our a we cash the our for burn, operating financial existing of believe and expect readouts be clinical it our discipline, programs in including cash clinical XXX are XXXX. to investments ongoing operations our balance as trial

call the hand now will back I to that, Dr. final With for Taylor? comments. Taylor Schreiber

Taylor Schreiber

Andrew. you, Thank

we execution a in you’ve are which intensely As our we just XXXX to on key pleased programs heard, approaching focused and XXXX. clinical in clinical be data of the are was year

updates including initial expected from cancer doxorubicin in platinum-resistant XXX in also are As the you in clinical liposomal heard patients trial from program the dose-escalation from Lini, ovarian data complete patients monotherapy combination ovarian data and XXXX. mid-year with cancer

from high-risk in initial in-patients first-half Additionally, data with the trial and our MDS XXXX. expected are AML of

see, As forward a be XXXX you data look to data-rich expect and we sharing to you. can those year with we

GADLEN as of platform preclinical development highlight respectively. Officers leading progress teams. Scientific the doctors Silva development of expertise Chief head cornerstones team’s to to of I research the the Shattuck One the promotion always our the been must efforts, development and Fromm and has in research and de and tremendous of and ARC XXXX,

activity continued distinct the other of our platform development design is we from and harnessing in build unique believe T Delta features. cancer Gamma approaches Cells all due to to in its truly has in GADLEN currently Interest

and During evaluating second for highlighted that antigen we which evaluating solid autoimmune preclinical development we development of from are in compounds are CDXX disease targeting in a for certain quarter the GADLEN BX-HX one the the fourth tumors. antigen we targeting two for XXXX, platform, the

to forward as providing advance later this GADLEN on We it look to further the guidance year. program continues

portfolio value. clinic monetize our remain discovery in shareholder continue and in investigate addition the and increase to would our to In underscore financial efforts, opportunities progress we that I to to like strong position our other to our

protein in next of financial puts believe our beyond the We in that participating in today’s and an resources strong as and milestones XXXX. experienced position our thank call. want I team of science combination everyone engineering, for well transformational set to incredibly to move as us

you to will objectives. we as and We keep execute of our apprised our strategic continue corporate progress

now would for like the questions. Operator? With your we open that, call to

Operator

afternoon will our question We Thank first you, Instructions] Dr. Jonathan Schreiber. take of ISI. [Operator Miller this from Evercore

Jonathan Miller

love release, wondering be grade, Grade how so the of a Have we in forward. were seems the cohort? to mg good combo relative in any tox liver patients you the just at taking move combo for should the available to I you or of that, in I’d XXX be and I out is any question. high half? in it you Thanks Hi, X tox I’m much how expect filling AML as seen X CDXX’s liver know off build some guys. And program. ORR to doses. many start to you with expect initial seeing in to that higher this do to getting that comp should especially MDS, be enough other these releases say,

Taylor Schreiber

question. Jon, Hey, the thanks for

combination in can in seen regard So the to the With escalation. coming similar guidance monotherapy the on I’ll tox, all of – numbers dose that Lini up cohorts. we’ve the you what patient we’re seeing provide studies profile to is all in

molecules well dose and tolerated as to between the study any in specific monotherapy of regard tox with mg/kg escalation any So well. X as that not question, monotherapy toxicity seeing evidence the cumulative liver we’re was

from looking in evidence that from anemias. So dose what the cytokine syndrome saw profile release also to far so consistent with perspective, destructive escalation of or good no monotherapy regard we

Lini Pandite

Then the relapsed AML, cohort, disease. combination, patients patients the escalation on who refractory enrolling the are with in have the that Jon, MDS dose we’re

of middle patients. just the are and by a context, XX have of agents, excess in in patients. expect targeted a monotherapy this the in the setting benchmark pump treatment-naive frontline patients cohorts the put to in – The they patients custom These relapsed/refractory the We year. CDXX

as cohorts We soon complete in frontline expansion setting dose starting will the be escalation. those we the as

Jonathan Miller

will back I much. so in Thanks sense. queue. Makes

Operator

go We next at Frahm you. Marc to now Cowen. Thank

Marc Frahm

similar broader the remarks, the the Maybe then you we selected Taylor, Doxil And because towards bio the course, questions. to ask scope has related go the but the presentation your I’ll the but Lini, Thanks going test. population. for prepared kind taking micro that’s update kind trial of May questions be mirve response an is of to as that, in enroll on approved see. likely population, to will or to we rate prep give and of that that in a mentioned if dataset, combo can of my just mirvetuximab get you

that of think patients will kind interpreting plus much proposed So, as of not benefit is response about we aren’t monotherapy how given include who you your should approved as durability on for get that data we not it some on the really so rate.

Taylor Schreiber

Marc. Lini Thanks, Great. for handle it us. can

Lini Pandite

patients something to are middle the expecting with Doxil XX of Yes, XX of the order year. we the the by in

guidance So be data be on And we efficacy. that we middle the the year. of based what as to provide will closer the depending of that to the mixture as as Doxil safety, to But both will would on order answer to to would – some it expect data, of we It well patients. expect the a the the be enrollment. in in XX time by question your the XX sharing

the high data, yes, approved greater. weight with I here or mean, patients XX% expresser looking With enrolling so and in at the group, mirve are with the mirve, mirve of XX% we

at are hope them interesting and data. have datasets by So that to doing database, of response will against subgroup benchmark response about to year, they or to what an patients have is we XX those to are their working looking be the see we see end will of what definitely the would with of that response And the rate have. durability we ImmunoGen the based expect be by subset. would we be with stage, data the we at on with worth in of this partnering we that ImmunoGen But

Marc Frahm

helpful. very you, Thank

Operator

Nochomovitz Yigal Citi. to now Thank you. We at go next

Yigal Nochomovitz

bar as What generally in the by XXX AML the a setting frontline mutant, the relapsed/refractory in study and in thanks. for well feeling setting. the might relapsed/refractory aza MDS combo of in combo expectations and with TPXX itself do you setting, the what as XXX believe see with the in to both as both for Hi, the you aza get efficacy addition I’m with to is in frontline for as trying above just well aza? expect

Taylor Schreiber

Yigal. Thanks,

As Lini an said to initial HMA the trial, in experienced primarily enrolling the we’re subject. portion of venetoclax

in So perhaps be frontline I provide might that you relapsed/refractory expect the in what would some setting. toward setting, and think any guidance activity helpful

are year There of setting are in cohorts the that effect complete TPXX The first in expected data mutant second patients. two the expect have XX%. AML terms in for to the of alone, frontline range one we believe that from azacitidine this responses the in we half of in the number

so looking high-risk honestly, of expected the a continues is. blurriness, for XX% to where as or field response to the azacitidine we’re in And MDS combination is what the of size effect so. a in rate complete bit this cohort, the And of in neighborhood there be alone

the Some complete high as be in Pevonedistat study could response of recent more it the XXs. studies teens, the the older as Takeda that place high with suggest rate that low

rate And so think the cite best we it’s higher benchmark. as response the to

a in looking response for And neighborhood for so complete responses. somewhere we’re XX% the combination of rate

Yigal Nochomovitz

sure you that the go What and for mentioned just I’m driving in then X you if decision? choice it Okay, the with just again not combo through doxorubicin. remarks, of the was XXX the liposomal in of can kind mg/kg prepared but

Taylor Schreiber

was it by So few a driven factors.

achieved full terms receptor occupancy and all, sides And dose visible in the of was to looking of that of receptor and CDXX mg/kilogram both the and that where on non-linearity molecule, profile. that were PK by X dose receptor CDXX the in a saturation the data First find occupancy observation we was of both was and binding achieved.

a the led were looking of by induction driven dose maximal pharmacodynamic Beyond effects that, that we for CDXX. to

receptor pharmacodynamic a are CDXX only is you folks that with like others – aware see effect inhibitors, in study the So with occupancy. many this

X the maintained mg maximal is maximal dose of the CDXX margination per was agent cells that effect kg dose XXX peripheral a plateau from That observation other expressing unique the space. mg/kg XX for to and So by rapid any of through dose. blood post the the relative up in

those CCLX, what importantly CCLX, primary cytokines including mg/kg not of rapid by mg/kg the effects were and appear a decline. interleukin-XX, achieved to that didn’t did IP-XX, by multiple other X maximal – be of a escalate cytokines, CCLXX a dose, also appreciably The number but pharmacodynamic dose, XX also plateau others. induction which And

of that right CDXX single-acting the or bring those was of And so prior so all response to from us the toxicity that both dose markers, CDXX effects of lacked bell-shaped gave agonist confidence all this on the inhibitors XXX differentiated and about in characterize and combos. dose any being

Yigal Nochomovitz

Great. Thank you.

Operator

you. Thank

We will question from Zhiqiang last Berenberg. today take of Shu our

Zhiqiang Shu

XXX XXX, for much. to questions. particularly PK/PD this is talk My XXX Obviously, consistent what wondering in can afternoon. the you around what Good are not from if PK/PD observing is the was you it’s your surprising to but program. learnings see about XXX? Thanks taking question Thanks discontinuation there, related the aspect the the I very with from to program,

Taylor Schreiber

you. thank Zhi. Sure,

cross that And here dose And completed peripheral trial expressing binding dose CDX through tolerated. the well saw quite cells of blood migration cells escalation post dose dose. of and So comparisons that with valuable. are, continued OXXX dose we program, to to those dependent we out extremely I be XXX escalation, the compound across XX the think, mg/kg

and of effects one dose terms response central the XXX observe – engage prior tolerability toxicities evidence hexameric so the of receptors agonist hypotheses pharmacodynamic regimens seen. bell-shaped the of helpful from and with of the that validating any are receptor abnormal ARC TNF that a pharmacodynamic if with a pharmacodynamic a some you not curve the And will of TNF XXX effects platform and and of have you antibody-based drug, again, perspective, lack in both

and population, a we’re – CDX learning positive, escalation at clear was important And really patients. CDXX all OXXX cytokines, molecule, achieve It cells terms data to both cancer XXX the quiet are no what only safety agent. So in look that’s there appreciable to the what specific in you much number the CDXX in serum whereas pharmacodynamic of clearly were more of the were a this standpoint, also in escalations that some common when positive platform migrating been have important led OXXX across I and were think much with agonist the an speak, there lessons cytokine human more from finding a And expansion The and reactions note the again from stimulation patient infusion-related you side. dose so cells. immunologically changes. that very that

And very differentiation the so paints this here. target-mediated the that in activity two biology constructs we’re a clear picture between that is seeing

to like So down this, I but think benefit this always hard from a learn learned we’ve other compounds program close molecule moving what learnings we to will needed those and forward.

Zhiqiang Shu

on maybe development disclosed, the you more of And with about Thanks. from assay. those preclinical when can you then have you last I Great. time just or platform, programs? quickly and sort more prioritization talk Can GADLEN see two think we consistent data there two that

Taylor Schreiber

they GADLEN T Delta And cells, cell alpha we’re co-stimulatory the a the require one heterodimer. So cell. seeking in and achieve expressed molecule And one the in engagers, the autoimmune to GADLEN with and a to about target just to require what from believe GADLEN lot clinical we’re activated. a a Cells for be we T T is select antibody-mediated molecules what by differentiate And their also the most disease. from considering with that CDX-based considering where antibody is BX-HX learned development indication for we’ve be comes to butyrophilin will receptor CDXX the ligands molecule the upon stimulus, that initial oncology it T development rely likely platform they will the we’re an is which molecule and cell be antigen-specific fully Gamma like beta itself study

of that tumor express we signal autoimmune might assure escalation that’s tumors X have that express actually signal can are that at the effort on early tumor. looking form on enroll XX. on a And the their the guiding so a those the any of B-cell, part patients also Phase to likely and or is ligands in BX-HX dose trying the is that ligand side to you and that exercise in to express CDXX side, which expresses And certainty will CDXX a to study

some are that the for And guidance of to this look trial study providing is X like so those we and to more year. principles Phase have that as specific mind in that be we what in going exactly design will short-term the

Zhiqiang Shu

Thanks, Great. Taylor.

Taylor Schreiber

Thank you.

Operator

Schreiber, you. This the turn call. closing of Taylor over Chief Executive for this remarks. to time, At Q&A Thank concludes the Shattuck call I of session Labs the like Officer back to would

Taylor Schreiber

and all of for the Thank We appreciate financial Thank quarter business our conference to we continued and year exciting call. in you, joining throughout remainder Shattuck operator look milestones updating thank to update you. an and you results forward full XXXX. the fourth interest on you XXXX we and Shattuck your what hope be

Operator

of you today’s Bye-bye. ladies Again, so you. just and thank to great all We conclude joining wish Thank day. much gentlemen, that remainder call. will your conference like for us and you a all

Shattuck Labs (STTK) 23 Feb 232022 Q4 Earnings call transcript